Proteasome inhibitor
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer. In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S.
A derivative of epigallocatechin-3-gallate has been proposed as another proteasome inhibitor.[1]
References
- ↑ Osanai K, Landis-Piwowar KR, Dou QP, Chan TH (2007). "A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer". doi:10.1016/j.bmc.2007.05.041. PMID 17544279.